Navigation Links
Nurses as effective as doctors in treatment of HIV patients
Date:8/14/2012

cal need to improve access to antiretroviral drugs not only in South Africa but in other low to middle income countries where infection rates are high and doctors are in short supply. HIV programmes worldwide should now consider expanding nurse-centred care, safe in the knowledge that there need not be detrimental effects on patient health or mortality rates if done carefully."

The study is the first to explore 'task-shifting' from doctors to nurses on such a large scale. It ran from 2008 to 2010 and was funded by the UK Medical Research Council, Development Co-operation Ireland, and the Canadian International Development Agency. The project was limited to South Africa, but the findings could have relevance in the West where antiretroviral treatment is usually provided by specialist hospital doctors.

Prof Bachmann and colleagues are currently undertaking further research to explore the cost-effectiveness of task-shifting HIV care from doctors to nurses, as well as strengthening the primary care of other chronic diseases.


'/>"/>

Contact: Simon Dunford
s.dunford@uea.ac.uk
44-160-359-2203
University of East Anglia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Phone contact with nurses linked with better outcomes for women with gestational diabetes
2. Nurses need to counteract negative stereotypes of the profession in top YouTube hits
3. Burnt-Out Nurses Linked to More Hospital Infections
4. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
5. Pig stomach mucins are effective as anti-viral agents for consumer products
6. Lower-Dose Radioiodine Effective Against Thyroid Cancer
7. Aspirin as Effective as Warfarin for Heart Failure: Study
8. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
9. Breast cancer effectively treated with chemical found in celery, parsley by MU researchers
10. Researchers make promising discovery in pursuit of effective lymphoma treatments
11. Breast MRI helps predict chemotherapys effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... PINES, FL (PRWEB) June 03, 2015 The ... event as part of the Veterans Health Administration’s (VHA) National ... place in the JC Cobb room located on the first ... 10:00 a.m. to 4:00 p.m. Women Veterans and their ... are invited to attend. To download a printable event flyer, ...
(Date:6/3/2015)... Norcross, GA (PRWEB) June 03, 2015 ... officially named the winner of its 2015 U.S. Education ... Power Portfolio in a college or university in the ... a GIScience student focused on Remote Sensing and Civil ... winning study, titled, “Pavement Surface Cracks Detection and Assessment ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Johnson & ... pay $7.8 million to resolve a Risperdal lawsuit ( ... tactics the company allegedly used to market the antipsychotic ... Court indicate that the Arkansas Attorney General moved to ... the accord. The Risperdal settlement amounts to just a ...
(Date:6/3/2015)... 2015 On June 22, 2015, Medicare ... drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009. ... as 19 million of the 49 million Medicare beneficiaries in ... life-threatening adverse drug events.(1) Sadly, if it became a standard ... Medicine, the use of an individual’s genetic information to tailor ...
(Date:6/3/2015)... Array Health , a leading ... that CEO Jonathan Rickert will present at America’s ... 4, 2015. The session will address the how the ... business models in health care, and why they are ... Digital Transformation and the Health Care Enterprise: Driving Business ...
Breaking Medicine News(10 mins):Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 2Health News:Bay Pines to Host National Women Veterans Campaign Event June 12 3Health News:Hexagon Geospatial Announces U.S. Education Challenge Winner at HxGN Live 2015 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2
... the pain-balm segment, with a market share of 70 ... Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu ... SmithKline India (GSK) has decided to transfer its Iodex ... a GSK subsidiary. SKBCH has a strong marketing and ...
... the most common cancer among women. It accounts for ... more than 23,000 new cases diagnosed in 2001. Progestin ... the highest// level of protection against ovarian cancer. Analysis ... study showed that the pill can help prevent ovarian ...
... disease that affects at least 39 million Americans, and ... to describe the problem. One in five Americans is ... raises the risk of many potentially fatal health conditions//, ... is linked to at least 300,000 deaths in the ...
... studying eight cross-gender heart transplants from New York Medical ... the heart after injury.// The research explodes the long-standing ... finding has implications for heart disease treatment. ... damaged heart much as it does other organs came ...
... non-steroidal anti-inflammatory drug (NSAID) treatment has shown that ... the risk of ulcer formation.// Treatment with omeprazole ... infections and reduced the six-month ulcer probability of ... to 12 per cent in the NSAID-treated arthritis ...
... discovered molecules in the body that can protect ... research, the research could potentially lead to the ... been linked with ailments such as cardiovascular disease, ... and Alzheimer’s disease. ,The researchers from ...
Cached Medicine News:
(Date:6/3/2015)... , June 3, 2015  PARI Respiratory Equipment has ... ® .  Kitabis Pak, approved by the FDA on December ... with a PARI LC PLUS ® Nebulizer for patients ... the hard work we put into this unique product offering ... is easy for patients to use, we also wanted to ...
(Date:6/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/t3kkhg/the_future_of ) ... Future of Pharmaceutical Outsourcing" report to their ... desperate need to develop better drugs with high ... been increasingly utilizing external resources to increase their ... their internal operation. Their outsourcing demands and proportions ...
(Date:6/3/2015)... , June 3, 2015 Mylan N.V. (Nasdaq: ... the Company will present at Goldman Sachs 36 th ... presentation is scheduled to begin at 4 p.m. PT / ... a live webcast of the presentation via the investor relations ... Mylan is a global pharmaceutical company committed to setting ...
Breaking Medicine Technology:Kitabis Pak Wins American Package Design Award 2The Future of Pharmaceutical Outsourcing: 2015 Report 2
... (NYSE: SHP ) ("ShangPharma" or the "Company"), a ... today announced that it will release its unaudited financial results ... May 19, 2011. Management will host a conference call to ... 19, 2011 (8:00pm Beijing time on May 19, 2011). ...
... 2011 Mithridion, Inc., a privately-owned clinical stage drug ... disorders, announces that the U.S. Food and Drug Administration ... lead drug candidate, for the treatment of Progressive Supranuclear ... to seven years of market exclusivity upon approval of ...
Cached Medicine Technology:ShangPharma Corporation to Announce First Quarter 2011 Financial Results on May 19, 2011 2FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy 2FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy 3
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve...
Ideal for short scleral tunnel and trabecular meshwork incisions...
Medicine Products: